Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T07:13:13.281Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Trials of Xenotransplantation: Waiver of the Right to Withdraw from a Clinical Trial Should Be Required

Published online by Cambridge University Press:  01 January 2021

Monique A. Spillman  and
Robert M. Sade
Get access Rights & Permissions [Opens in a new window]

Extract

Xenotransplantation is defined as “any procedure that involves the transplantation, implantation, or infusion into a human recipient of either (a) live cells, tissues, or organs from a nonhuman animal source, or (b) human body fluids, cells, tissues or organs that have had ex vivo contact with live nonhuman animal cells, tissues, or organs.” Xenotransplantation has been viewed by desperate patients and their surgeons as a solution to the problem of the paucity of human organs available for transplantation. Foes of xenotransplantation argue that the use of animal organs degrades the human race and should be avoided.

In this paper, we briefly review the cultural context of xenotransplantation and explore the infectious disease risk of xenotransplantation. The United States Code of Federal Regulations requires life-long surveillance of a xenotransplantation recipient due to the largely unknown risk of novel infectious disease transmitted across species, known as xenogeneic infectious disease. We argue that despite being in the interest of protecting the public health, the imposition of lifelong surveillance requirements on xenotransplant recipients effectively abrogates the right to withdraw from a clinical trial after the transplantation has taken place. Moreover, we argue that a waiver of the right to withdraw should be made explicit in the interest of full disclosure, out of respect for the research subject’s right of self-determination.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 35 , Issue 2 , Summer 2007 , pp. 265 - 272
Copyright
Copyright © American Society of Law, Medicine and Ethics 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

United States Public Health Service, Department of Health and Human Services, Guideline on Infectious Disease Issues in Xenotransplantation, January 19, 2001, at 15 [hereinafter cited as Guideline].Google Scholar
Hammer, C., “Comments on Ethics in Human Xenotransplantation,” in Cooper, D. K. C., Kemp, E., Platt, J. L. and White, D. J. G., eds., Xenotransplantation: The Transplantation of Organs and Tissues between Species (Berlin: Springer-Verlag, 1997): 766–773, at 769.CrossRefGoogle Scholar
Deschamps, J.-Y., Roux, F. A., Sai, P. and Gouin, E., “History of Xenotransplantation,” Xenotransplantation 12 (2005): 91–109, at 96.CrossRefGoogle Scholar
Id., at 93, Table 4.Google Scholar
Malouin, R., “Surgeons' Quest for Life: The History and the Future of Xenotransplantation,” Perspectives in Biology and Medicine 37, no. 3 (1994): 416–428, at 421–423.CrossRefGoogle Scholar
Id.Google Scholar
See Deschamps, et al., supra note 3, at 98.Google Scholar
Bach, F. and Fineberg, H., “Call for Moratorium on Xenotransplants,” Nature 391 (1998): 326.CrossRefGoogle Scholar
Chapman, L. E., “Zoonosis as a Risk to the Xenograft Recipient and to Society: Theoretical Issues,” in Platt, J., ed., Xenotransplantation (Washington, D.C.: ASM Press, 2001): 207–216, at 208.Google ScholarPubMed
Weiss, R. A., “Retroviruses and Xenotransplantation,” in Platt, J., ed., Xenotransplantation (Washington, D.C.: ASM Press, 2001): 239–250, at 243.Google Scholar
Karesh, W. B. and Cook, R. A., “The Human-Animal Link,” Foreign Affairs 84, no. 4 (2005): 38–50, at 41.CrossRefGoogle Scholar
Id.Google Scholar
Matthews, P. J., “Zoonotic Agents: Swine to Humans,” in Platt, J., ed., Xenotransplantation (Washington, D.C.: ASM Press, 2001): 217–238, at 235.Google Scholar
Id.Google Scholar
See Guideline, supra note 1, at 14.Google Scholar
Committee on Xenograft Transplantation: Ethical Issues and Public Policy, Division of Health Sciences Policy, Division of Health Care Services, Institute of Medicine, Xenotransplantation: Science, Ethics, and Public Policy (Washington, D.C.: National Academy Press, 1996) at 92.Google Scholar
Fishman, J. A., “Prevention of Infection in Xenotransplantation,” in Platt, J., ed., Xenotransplantation (Washington, D.C.: ASM Press; 2001): 261–290, at 272.Google ScholarPubMed
Id., at 276.Google Scholar
Patience, C., Takeuchi, Y. and Weiss, R. A., “Infection of Human Cells by an Endogenous Retrovirus of Pigs,” Nature Medicine 3, no. 3 (1997): 282–286.CrossRefGoogle Scholar
See Deschamps, et al., supra note 3, at 103.Google Scholar
Baertschiger, R. M. and Buhler, L. H., “Xenotransplantation Literature Update November-December, 2004,” Xenotransplantation 12 (2005): 156–160, at 157.CrossRefGoogle Scholar
Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Guidance for Industry: Precautionary Measures to Reduce the Possible Risk of Transmission of Zoonoses by Blood and Blood Products from Xenotransplantation Product Recipients and Their Contacts, December, 1999.Google Scholar
Id., at 4.Google Scholar
See Guideline, supra note 1, at 20–22, 35–38.Google Scholar
Id., at 20.Google Scholar
Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans: FINAL GUIDANCE, April, 2003, i-60, at 48 [herein cited as Guidance for Industry].Google Scholar
See Guideline, supra note 1, at 21.Google Scholar
Id., at 35.Google Scholar
Id., at 36.Google Scholar
Id.Google Scholar
Id., at 37.Google Scholar
Id.Google Scholar
See Guidance for Industry, supra note 26, at 49.Google Scholar
See Guideline, supra note 1, at 21.Google Scholar
Id.Google Scholar
See Guidance for Industry, supra note 26, at 56.Google Scholar
See Guideline, supra note 1, at 42.Google Scholar
Caplan, A. L., “Is Xenografting Morally Wrong?” in Caplan, A. L. and Coelho, D. H., eds., The Ethics of Organ Transplants (Amherst, New York: Prometheus Books, 1998): 121–132, at 131.Google Scholar
U.S. National Commission for the Protection of Human Subjects of Biological and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Department of Health, Education, and Welfare (DHEW), Publication No. (OS) 78–0012, Appendix I, DHEW Publication No. (OS) 78–0013, Appendix II, DHEW Publication No. (OS) 78–0014, U.S. Government Printing Office, Washington, D.C., 1978.Google Scholar
World Medical Association, “World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects,” JAMA 284, no. 23 (2000): 3043–5.CrossRefGoogle Scholar
See Guideline, supra note 1, at 19–20.Google Scholar
M. Sykes, A. d'Apice, and M. Sandrin on behalf of the IXA Ethics Committee, “Position Paper of the Ethics Committee of the International Xenotransplantation Association,” Transplantation 78, no. 8 (2004): 1101–1107, at 1103.CrossRefGoogle Scholar
Florencio, P. S. and Ramanathan, E. D., “Legal Enforcement of Xenotransplantation Public Health Safeguards,” Journal of Law, Medicine & Ethics 32, no. 1 (2004): 117–123, at 118.CrossRefGoogle Scholar
Id.Google Scholar
Cooper, D. K. C. and Lanza, R. P., eds., XENO: The Promise of Transplanting Animal Organs into Humans (New York: Oxford University Press, 2000): at 217.Google Scholar
See Florencio, supra note 43, at 119.Google Scholar
United States Supreme Court O'Connor v. Donaldson, 422 U.S. 563 (1975).Google Scholar
See Florencio, , Ramanathan, supra note 46.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id., at 120.Google Scholar
Spellecy, R., “Reviving Ulysses Contracts,” Kennedy Institute of Ethics Journal 13, no. 4 (2003): 373–392, at 375.CrossRefGoogle Scholar
Id., at 375; personal communication with author, January 10, 2006.Google Scholar
Id., at 373.Google Scholar
See Sykes, et al., supra note 42, at 1103.Google Scholar
See Spellecy, supra note 52, at 374.Google Scholar
Id., at 375.Google Scholar
Battey, J. F., National Institutes of Health: Support for Human Embryonic Stem Cell Research, paper presented at the Forum for Medical Affairs, Dallas, Texas, November, 6, 2005.Google Scholar